Proposed Data Collections Submitted for Public Comment and Recommendations, 49622-49623 [05-16367]
Download as PDF
<![CDATA[
49622
Federal Register / Vol. 70, No. 163 / Wednesday, August 24, 2005 / Notices
annual report. The ability to collect data
through Internet accessibility will allow
for a more streamlined and efficient use
of data processing by the states and
reduce the states’ burden of duplicate
reporting on outcome and risk factor
data. There is no cost to respondents
except their time to complete the
application/report. The total estimated
annualized burden hours are 4270.
ESTIMATED ANNUALIZED BURDEN TABLE
No. of
respondents
Forms
Annual Applications .....................................................................................................................
Annual Reports ............................................................................................................................
*61
61
No. of
responses/respondent
Average
burden per response
(hours)
1
1
30
40
* There are 61 respondents (Official State Health Agencies from the 50 States, the District of Columbia, 8 U.S. Territories, and two American
Indian Tribes (Santee Sioux and Kickapoo of Kansas). The response burden consists of an annual application and an annual report (with selected summary data items).
Dated: August 11, 2005.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 05–16366 Filed 8–23–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–05–03AA]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 371–5983 or send an
e-mail to omb@cdc.gov. Send written
comments to CDC Desk Officer, Human
Resources and Housing Branch, New
DNA integrity, reproductive hormone
levels, and prostate specific antigen
(PSA) levels.
Neurobehavioral effects will be
assessed using sensation-tactile,
postural stability, grooved pegboard,
and simple reaction time tests. Two
questionnaires will be administered on
one occasion. Questionnaire
information will be collected
concurrently to augment test
interpretation, adjust for potential
confounders and covariates during
regression analysis, correlate specific
jobs and job activities with exposure
measurements, and for validation
purposes. Findings from this study will
clarify if the adverse reproductive
effects observed in animal studies are
also present in acrylamide-exposed
male workers, and if preclinical
neurobehavioral deficits are present at
acrylamide doses currently considered
to be within safe limits. This study is
scheduled for implementation between
2005 and 2007. There is no cost to the
respondent other than their time for
participating. The annualized estimated
burden for this data collection is 54
hours.
Executive Office Building, Room 10235,
Washington, DC 20503 or by fax to (202)
395–6974. Written comments should be
received within 30 days of this notice.
Proposed Project
Potential Reproductive and
Neurological Effects of Exposure to
Acrylamide—NEW—The National
Institute for Occupational Safety and
Health (NIOSH), Centers for Disease
Control and Prevention (CDC).
The mission of the National Institute
for Occupational Safety and Health
(NIOSH) is to promote safety and health
at work for all people through research
and prevention. Consistent with this
mission, NIOSH is undertaking a study
of the reproductive and neurobehavioral
effects of occupational exposure to
acrylamide. Male acrylamide workers
and control workers (N = 100 per group)
will be recruited from manufacturing,
end-user, and non-exposed settings.
Exposure will be characterized by
acrylamide hemoglobin, adduct and
urinary metabolite levels, ambient area,
personal air, and dermal sampling.
Reproductive effects will be evaluated
by examining semen quality, sperm
ESTIMATE OF ANNUALIZED BURDEN TABLE
Number of
respondents
Survey questionnaires
Medical & Reproductive History Questionnaire ...........................................................................
Occupational History Questionnaire ............................................................................................
Non-participant Questionnaire .....................................................................................................
VerDate jul<14>2003
15:23 Aug 23, 2005
Jkt 205001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
E:\FR\FM\24AUN1.SGM
67
67
17
24AUN1
Number of
responses/respondent
1
1
1
Average
burden/response
(hours)
13/60
34/60
2/60
Federal Register / Vol. 70, No. 163 / Wednesday, August 24, 2005 / Notices
Dated: August 11, 2005.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 05–16367 Filed 8–23–05; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Cooperative Agreement To Build Local
Capacity To Respond to the HIV/AIDS
Epidemic in the Caribbean, as Part of
the President’s Emergency Plan for
AIDS Relief
Announcement Type: New.
Funding Opportunity Number: CDC–
RFA–AA157.
Catalog of Federal Domestic
Assistance Number: 93.067.
Key Dates: Application Deadline:
September 19, 2005.
I. Funding Opportunity Description
Authority: This program is authorized
under sections 301 and 307 of the Public
Health Service Act [42 U.S.C. 24l and 2421,
as amended, and under Public Law 108–25
(United States Leadership Against HIV/AIDS,
Tuberculosis and Malaria Act of 2003) [22
U.S.C. 7601].
Background: President Bush’s
Emergency Plan for AIDS Relief has
called for immediate, comprehensive
and evidence-based action to turn the
tide of global HIV/AIDS. The initiative
aims to treat more than two million
HIV-infected people with effective
combination anti-retroviral therapy by
2008; care for ten million HIV-infected
and affected persons, including those
orphaned by HIV/AIDS, by 2008; and
prevent seven million infections by
2010, with a focus on 15 priority
countries, including 12 in sub-Saharan
Africa. The five-year strategy for the
Emergency Plan is available at the
following Internet address: https://
www.state.gov/s/gac/rl/or/c11652.htm.
With an average adult HIV prevalence
of 2.3 percent, the Caribbean is the
second-most affected region in the
world, according to the 2004 Annual
Report from the Joint United Nations
Programme on HIV and AIDS
(UNAIDS). Overall, the highest HIVinfection levels among women in the
Americas are in Caribbean countries,
and AIDS has become the leading cause
of death in the Caribbean among adults
aged 15–44 years (Caribbean
Epidemiology Centre, Pan-American
Health Organization (PAHO), World
Health Organization (WHO), 2004). A
VerDate jul<14>2003
15:23 Aug 23, 2005
Jkt 205001
regional response to HIV/AIDS is
necessary in the Caribbean because of
population mobility, the limited
response capacity of individual
countries, and the need for a
multisectoral, collaborative strategy (A
Study of the Pan Caribbean Partnership
Against HIV/AIDS 2004).
Purpose: The purpose of this funding
announcement is to build progressively
an indigenous, sustainable response to
regional HIV epidemic in the Caribbean
through the rapid expansion of
innovative, culturally appropriate, highquality HIV/AIDS prevention and care
interventions, and improved linkages to
confidential HIV counseling and testing
and HIV treatment services by targeting
rural and other underserved populations
in the West Indies.
Under the leadership of the U.S.
Global AIDS Coordinator, as part of the
President’s Emergency Plan, the U.S.
Department of Health and Human
Services (HHS) works with host
countries and other key partners to
assess the needs of each country and
design a customized program of
assistance that fits within the host
nation’s strategic plan.
HHS focuses on two or three major
program areas in each country. Goals
and priorities include the following:
• Achieving primary prevention of
HIV infection through activities such as
expanding confidential counseling and
testing programs, building programs to
reduce mother-to-child transmission,
and strengthening programs to reduce
transmission via blood transfusion and
medical injections.
• Improving the care and treatment of
HIV/AIDS, sexually transmitted diseases
(STDs) and related opportunistic
infections by improving STD
management; enhancing care and
treatment of opportunistic infections,
including tuberculosis (TB); and
initiating programs to provide antiretroviral therapy (ART).
• Strengthening the capacity of
countries to collect and use surveillance
data and manage national HIV/AIDS
programs by expanding HIV/STD/TB
surveillance programs and
strengthening laboratory support for
surveillance, diagnosis, treatment,
disease-monitoring and HIV screening
for blood safety.
Measurable outcomes of the program
will be in alignment with the numerical
goals of the President’s Emergency Plan
for AIDS Relief and one (or more) of the
performance goal(s) for the HHS/CDC
National Center for HIV, Sexually
Transmitted Disease and Tuberculosis
Prevention (NCHSTP) within HHS:
Increase the proportion of HIV-infected
people who are linked to appropriate
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
49623
prevention, care and treatment services;
strengthen the capacity nationwide to
monitor the epidemic; develop and
implement effective HIV prevention
interventions; and evaluate prevention
programs.
This announcement is only for nonresearch activities supported by HHS,
including CDC. If an applicant proposes
research activities, HHS will not review
the application. For the definition of
‘‘research’’, please see the HHS/CDC
web site at the following Internet
address: https://www.cdc.gov/od/ads/
opspoll1.htm.
Activities: The recipient of these
funds is responsible for activities in
multiple program areas designed to
target underserved populations in the
Caribbean. Either the awardee will
implement activities directly or will
implement them through its subgrantees
and/or subcontractors; the awardee will
retain overall financial and
programmatic management under the
oversight of HHS/CDC and the strategic
direction of the Office of the U.S. Global
AIDS Coordinator. The awardee must
show a measurable progressive
reinforcement of the capacity of
indigenous organizations and local
communities to respond to the national
HIV epidemic, as well as progress
towards the sustainability of activities.
Applicants should describe activities
in detail as part of a four-year action
plan (U.S. Government Fiscal Years
2005–2008 inclusive) that reflects the
policies and goals outlined in the fiveyear strategy for the President’s
Emergency Plan.
The grantee will produce an annual
operational plan in the context of this
four-year plan, which the U.S.
Government Emergency Plan team on
the ground in the Caribbean will review.
The grantee may work on some of the
activities listed below in the first year
and in subsequent years, and then
progressively add others from the list to
achieve all of the Emergency Plan
performance goals, as cited in the
previous section.
Based on its competitive advantage
and proven field experience, the
winning applicant will undertake a
broad range of activities to meet the
numerical Emergency Plan targets
outlined above. For each of these
activities, the grantee will give priority
to evidence-based, yet culturally
adapted, innovative approaches.
Capacity-building technical assistance
activities covered under this cooperative
agreement are limited to the following:
1. Strengthen organizational
infrastructure of HIV prevention, care
and treatment programs located within
the Caribbean Region.
E:\FR\FM\24AUN1.SGM
24AUN1
]]>Agencies
[Federal Register Volume 70, Number 163 (Wednesday, August 24, 2005)]
[Notices]
[Pages 49622-49623]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-16367]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-05-03AA]
Proposed Data Collections Submitted for Public Comment and
Recommendations
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 371-5983 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Human
Resources and Housing Branch, New Executive Office Building, Room
10235, Washington, DC 20503 or by fax to (202) 395-6974. Written
comments should be received within 30 days of this notice.
Proposed Project
Potential Reproductive and Neurological Effects of Exposure to
Acrylamide--NEW--The National Institute for Occupational Safety and
Health (NIOSH), Centers for Disease Control and Prevention (CDC).
The mission of the National Institute for Occupational Safety and
Health (NIOSH) is to promote safety and health at work for all people
through research and prevention. Consistent with this mission, NIOSH is
undertaking a study of the reproductive and neurobehavioral effects of
occupational exposure to acrylamide. Male acrylamide workers and
control workers (N = 100 per group) will be recruited from
manufacturing, end-user, and non-exposed settings. Exposure will be
characterized by acrylamide hemoglobin, adduct and urinary metabolite
levels, ambient area, personal air, and dermal sampling. Reproductive
effects will be evaluated by examining semen quality, sperm DNA
integrity, reproductive hormone levels, and prostate specific antigen
(PSA) levels.
Neurobehavioral effects will be assessed using sensation-tactile,
postural stability, grooved pegboard, and simple reaction time tests.
Two questionnaires will be administered on one occasion. Questionnaire
information will be collected concurrently to augment test
interpretation, adjust for potential confounders and covariates during
regression analysis, correlate specific jobs and job activities with
exposure measurements, and for validation purposes. Findings from this
study will clarify if the adverse reproductive effects observed in
animal studies are also present in acrylamide-exposed male workers, and
if preclinical neurobehavioral deficits are present at acrylamide doses
currently considered to be within safe limits. This study is scheduled
for implementation between 2005 and 2007. There is no cost to the
respondent other than their time for participating. The annualized
estimated burden for this data collection is 54 hours.
Estimate of Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden/
Survey questionnaires respondents responses/ response
respondent (hours)
----------------------------------------------------------------------------------------------------------------
Medical & Reproductive History Questionnaire.................... 67 1 13/60
Occupational History Questionnaire.............................. 67 1 34/60
Non-participant Questionnaire................................... 17 1 2/60
----------------------------------------------------------------------------------------------------------------
[[Page 49623]]
Dated: August 11, 2005.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. 05-16367 Filed 8-23-05; 8:45 am]
BILLING CODE 4163-18-P
